Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia

Reference

• Hiddemann, W. (1991) "Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens", Ann. HematoL, 62, 119 — 128.
   Web of Science ®Google Scholar
• Rowe, J.M. (1998) "What is the best induction regimen for acute myelogenous leukemia?" Leukemia, 12\(Suppl 1), S16 — S19.
   PubMed Web of Science ®Google Scholar
• Burk, M., Heyll, A., Arning, M., Volmer, M., Fartash, K. and Schneider, W. (1997) "Pharmacokinetics of high-dose cytarabine and its deamination product—a reappraisal", Leuk. Lymphoma, 27, 321–327.
   PubMed Web of Science ®Google Scholar
• Del Poeta, G., Stasi, R., Aronica, G., Venditti, A., Cox, MC., Bruno, A., Buccisano, F., et al. (1996) "Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia", Blood, 87, 1997 — 2004.
   Google Scholar
• List, A.F., Spier, CS., Grogan, TM., Johnson, C., Roe, DJ., Greer, J.P., et al. (1996) "Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia", Blood, 87, 2464–2469.
   Google Scholar
• Michieli, M., Damiani, D., Ermacora, A., Masolini, P., Raspadori, D., Visani, G., et al. (1999) "P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implica-tions", Br. J. HaematoL, 104, 328–335.
   Web of Science ®Google Scholar
• van den Heuvel-Eibrink, MM., Wiemer, E.A., Prins, A., Meijerink, J.P., Vossebeld, P.J., van der Holt, B., et al. (2002) "Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)", Leukemia, 16, 833–839.
   Google Scholar
• Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, ML., Chen, I.M., et al. (1997) "Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytoge-netics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study", Blood, 89, 3323— 3329.
   Google Scholar
• Schuurhuis, G.J., Broxterman, Hi., Ossenkoppele, G.J., Baak, J.P., Eekman, CA., Kuiper, CM., et al. (1995) "Functional multidrug resistance phenotype associated with combined over-expression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia", Clin. Cancer Res., 1, 81–93.
   Web of Science ®Google Scholar
• Kufe, D.W., Major, P.P., Egan, E.M. and Beardsley, G.P. (1980) "Correlation of cytotoxicity with incorporation of ara-C into DNA", J. Biol. Chem., 255, 8997–8900.
   Web of Science ®Google Scholar
• Plagemann, PG., Marz, R. and Wohlhueter, R.M. (1978) "Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of tripho-sphate synthesis", Cancer Res., 38, 978–989.
   PubMed Web of Science ®Google Scholar
• Wiley, JS., Taupin, J., Jamieson, G.P., Snook, M., Sawyer, W.H. and Finch, L.R. (1985) "Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lympho-ma", J. Clin. Invest., 75, 632–642.
   Google Scholar
• Mackey, J., Baldwin, S.A., Young, J.D. and Cass, C.E. (1998) "Nucleoside transport and its significance for anticancer drug resistance", Drug Resistance Updates, 1, 310— 324.
   PubMed Web of Science ®Google Scholar
• Mackey, J.R., Mani, R.S., Seiner, M., Mowles, D., Young, JD., Belt, JA., et al. (1998) "Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines", Cancer Res., 58, 4349–4357.
   PubMed Web of Science ®Google Scholar
• Boleti, H., Coe, I.R., Baldwin, S.A., Young, J.D. and Cass, C.E. (1997) "Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells", Neuropharmacology, 36, 1167 — 1179.
   Google Scholar
• Coleman, C.N., Stoller, R.G., Drake, J.C. and Chabner, B.A. (1975) "Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes", Blood, 46, 791–803.
   Google Scholar
• Van Rompay, A.R., Johansson, M. and Karlsson, A. (1999) "Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme", MoL PharmacoL, 56, 562— 569.
   PubMed Web of Science ®Google Scholar
• Schneider, B., Xu, Y.W., Janin, J., Veron, M. and Deville-Bonne, D. (1998) "3'-Phosphorylated nucleotides are tight binding inhibitors of nucleoside diphosphate kinase activity", J. Biol. Chem., 273, 28773–28778.
   Web of Science ®Google Scholar
• Laliberte, J. and Momparler, R.L. (1994) "Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA", Cancer Res., 54, 5401 —5407.
   Google Scholar
• Galmarini, CM., Mackey, J.R. and Dumontet, C. (2001) "Nucleoside analogues: mechanisms of drug resistance and reversal strategies", Leukemia, 15, 875–890.
   Google Scholar
• Major, P.P., Egan, EM., Beardsley, G.P., Minden, M.D. and Kufe, D.W. (1981) "Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA", Proc. Natl. Acad. Sci. USA, 78, 3235–3239.
   PubMed Web of Science ®Google Scholar
• Major, P.P., Egan, EM., Herrick, DJ. and Kufe, D.W. (1982) "Effect of ARA-C incorporation on deoxyribonucleic acid synth-esis in cells", Biochem. PharmacoL, 31, 2937 — 2940.
   Web of Science ®Google Scholar
• Gunji, H., Kharbanda, S. and Kufe, D. (1991) "Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-beta-D-arabinofuranosylcytosine", Cancer Res., 51, 741–743.
   PubMed Web of Science ®Google Scholar
• Raza, A., Gezer, S., Anderson, J., Lykins, J., Bennett, J., Browman, G., et al. (1992) "Relationship of [3H]Ara-C incorpora-tion and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study", Exp. HematoL, 20, 1194 — 1200.
   Web of Science ®Google Scholar
• Estey, E., Plunkett, W., Dixon, D., Keating, M., McCreclie, K. and Freireich, E.J. (1987) "Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia", Leukemia, 1, 580–583.
   Google Scholar
• White, J.C., Rathmell, J.P. and Capizzi, R.L. (1987) "Membrane transport influences the rate of accumulation of cytosine arabino-side in human leukemia cells", J. Clin. Invest., 79, 380–387.
   Google Scholar
• Gati, W.P., Paterson, A.R., Larratt, L.M., Turner, A.R. and Belch, A.R. (1997) "Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein", Blood, 90, 346 — 353.
   Google Scholar
• Gati, W.P., Paterson, A.R., Belch, A.R., Chlumecky, V., Larratt, L.M., Mant, M.J., et al. (1998) "Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC)", Leuk. Lymphoma, 32, 45–54.
   PubMed Web of Science ®Google Scholar
• Baldwin, S.A., Mackey, J.R., Cass, C.E. and Young, J.D. (1999) "Nucleoside transporters: molecular biology and implications for therapeutic development", MoL Med. Today, 5, 216–224.
   Google Scholar
• Galmarini, C.M., Thomas, X., Calvo, F., Rousselot, P., Jafaari, A.E., Cros, E., et al. (2002) "Potential mechanisms of resistance to cytarabine in AML patients", Leuk. Res., 26, 621–629.
   Google Scholar
• Wiley, J.S., Jones, S.P., Sawyer, W.H. and Paterson, A.R. (1982) "Cytosine arabinoside influx and nucleoside transport sites in acute leukemia", J. Clin. Invest., 69, 479–489.
   Google Scholar
• Galmarini, C.M., Thomas, X., Calvo, F., Rousselot, P., Rabilloud, M., El Jaffari, A., et al. (2002) "In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia", Br. J. HaematoL, 117, 860–868.
   Web of Science ®Google Scholar
• Arner, E.S. and Eriksson, S. (1995) "Mammalian deoxyribonu-cleoside kinases", PharmacoL Ther., 67, 155— 186.
   Google Scholar
• Verhoef, V., Sarup, J. and Fridland, A. (1981) "Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases", Cancer Res., 41, 4478–4483.
   PubMed Web of Science ®Google Scholar
• Bhalla, K., Nayak, R. and Grant, S. (1984) "Isolation and characterization of a deoxycytidine kinase-deficient human pro-myelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine", Cancer Res., 44, 5029 — 5037.
   Google Scholar
• Stegmann, A.P., Honders, MM., Kester, M.G., Landegent, J.E. and Willemze, R. (1993) "Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcyto-sine and 5-aza-2'-deoxycytidine", Leukemia, 7, 1005–1011.
   Google Scholar
• Dumontet, C., Fabianowska-Majewska, K., Mantincic, D., Callet Bauchu, E., Tigaud, I., Gandhi, V., et al. (1999) "Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562", Br. J. HaematoL, 106, 78 — 85.
   Google Scholar
• Stegmann, A.P., Honders, W.H., Willemze, R., Ruiz van Haperen, V.W. and Landegent, J.E. (1995) "Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity", Blood, 85, 1188 — 1194.
   Google Scholar
• Hapke, D.M., Stegmann, A.P. and Mitchell, B.S. (1996) "Retro-viral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity", Cancer Res., 56, 2343–2347.
   PubMed Web of Science ®Google Scholar
• Orr, R.M., Talbot, D.C., Aherne, W.G., Fisher, T.C., Serafinowski, P. and Harrap, K.R. (1995) "2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines", Chit Cancer Res., 1, 391–398.
   PubMed Web of Science ®Google Scholar
• Owens, J.K., Shewach, D.S., Ullman, B. and Mitchell, B.S. (1992) "Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene", Cancer Res., 52, 2389–2393.
   PubMed Web of Science ®Google Scholar
• Kakihara, T., Fukuda, T., Tanaka, A., Emura, I., Kishi, K., Asami, K., et al. (1998) "Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia", Leuk. Lymphoma, 31, 405–409.
   PubMed Web of Science ®Google Scholar
• Stammler, G., Zintl, F., Sauerbrey, A. and Volm, M. (1997) "Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia", Anticancer Drugs, 8, 517 — 521.
   Google Scholar
• Flasshove, M., Strumberg, D., Ayscue, L., Mitchell, B.S., Tirier, C., Heit, W., et al. (1994) "Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside", Leukemia, 8, 780–785.
   Google Scholar
• Veuger, M.J., Honders, MW., Landegent, J.E., Willemze, R. and Barge, R.M. (2000) "High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia", Blood, 96, 1517— 1524.
   Google Scholar
• Chiba, P., Tihan, T., Szekeres, T., Salamon, J., Kraupp, M., Eher, R., et al. (1990) "Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo", Leukemia, 4, 761 —765.
   Google Scholar
• Chottiner, E.G., Shewach, D.S., Datta, N.S., Ashcraft, E., Gribbin, D., Ginsburg, D., et al. (1991) "Cloning and expression of human deoxycytidine kinase cDNA", Proc. Natl. Acad. Sci. USA, 88, 1531 — 1535.
   PubMed Web of Science ®Google Scholar
• Harris, AL., Grahame-Smith, D.G., Potter, C.G. and Bunch, C. (1981) "Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy", Clin. Sci. (Lond), 60, 191 — 198.
   Google Scholar
• Jahns-Streubel, G., Reuter, C., Auf der Landwehr, U., Unterhalt, M., Schleyer, E., Wormann, B., et al. (1997) "Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia", Blood, 90, 1968 — 1976.
   Google Scholar
• Jahns-Streubel, G., Reuter, C., Unterhalt, M., Schleyer, E., Wormann, B., Buchner, T., et al. (1995) "Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia", Leukemia, 9, 1857— 1863.
   Google Scholar
• Colly, L.P., Peters, W.G., Richel, D., Arentsen-Honders, MW., Starrenburg, C.W. and Willemze, R. (1987) "Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia", Semin. OncoL, 14, 257— 261.
   Google Scholar
• Tattersall, M.H., Ganeshaguru, K. and Hoffbrand, A.V. (1974) "Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside", Br. J. HaematoL, 27, 39–46.
   Web of Science ®Google Scholar
• Galmarini, CM., Thomas, X., Graham, K., El Jafaari, A., Cros, E., Jordheim, L., et al. (2003) "Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine", Br. J. HaematoL, 122, 53–60.
   Web of Science ®Google Scholar
• Taub, J.W., Matherly, L.H., Stout, ML., Buck, S.A., Gurney, J.G. and Ravindranath, Y. (1996) "Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia", Blood, 87, 3395–3403.
   Google Scholar
• Taub, J.W., Huang, X., Matherly, L.H., Stout, ML., Buck, S.A., Massey, G.V., et al. (1999) "Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relation-ship to in vitro sensitivity to cytosine arabinoside and daunor-ubicin", Blood, 94, 1393–1400.
   Google Scholar
• Taub, J.W., Huang, X., Ge, Y., Dutcher, J.A., Stout, ML., Mohammad, R.M., et al. (2000) "Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome", Cancer Res., 60, 6421 — 6426.
   Google Scholar
• Galmarini, C.M., Jordheim, L. and Dumontet, C. (2003) "Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignan-cies", Leuk. Lymphoma, 44, 1105–1111.
   PubMed Web of Science ®Google Scholar
• Boyle, J.M., Hey, Y., Guerts van Kessel, A. and Fox, M. (1988) "Assignment of ecto-5'-nucleotidase to human chromosome 6", Hum. Genet., 81, 88–92.
   Web of Science ®Google Scholar
• Resta, R., Hooker, SM., Hansen, KR., Laurent, A.B., Park, J.L., Blackburn, MR., et al. (1993) "Murine ecto-5'-nucleotidase (CD73): cDNA cloning and tissue distribution", Gene, 133, 171 — 177.
   Google Scholar
• Resta, R., Yamashita, Y. and Thompson, L.F. (1998) "Ecto-enzyme and signaling functions of lymphocyte CD73", ImmunoL Rev., 161, 95 — 109.
   Google Scholar
• Skladanowski, AC., Smolenski, R.T., Tavenier, M., de Jong, J.W., Yacoub, M.H. and Seymour, AM. (1996) "Soluble forms of 5'-nucleotidase in rat and human heart", Am. J. PhysioL, 270, H1493—H1500.
   Web of Science ®Google Scholar
• Hunsucker, S.A., Spychala, J. and Mitchell, B.S. (2001) "Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance", J. Biol. Chem., 276, 10498 — 10504.
   Web of Science ®Google Scholar
• Sala-Newby, GB., Skladanowski, AC. and Newby, AC. (1999) "The mechanism of adenosine formation in cells. Cloning of cytosolic 5'-nucleotidase-I", J. Biol. Chem., 274, 17789— 17793.
   Web of Science ®Google Scholar
• Spychala, J., Madrid-Marina, V. and Fox, I.H. (1989) "Evidence for "low Km" and "high Km" soluble 5'-nucleotidases in human tissues and rat liver", Adv. Exp. Med. Biol., 253B, 129–134.
   Google Scholar
• Itoh, R. (1993) "IMP-GMP 5'-nucleotidase", Comp. Biochem. PhysioL B, 105, 13 — 19.
   Web of Science ®Google Scholar
• Rampazzo, C., Johansson, M., Gallinaro, L., Ferraro, P., Hell-man, U., Karlsson, A., et al. (2000) "Mammalian 5'(3')-deoxyr-ibonucleotidase, cDNA cloning, and overexpression of the enzyme in Escherichia coli and mammalian cells", J. Biol. Chem., 275, 5409–5415.
   PubMed Web of Science ®Google Scholar
• Amici, A. and Magni, G. (2002) "Human erythrocyte pyrimidine 5'-nucleotidase, PN-I", Arch. Biochem. Biophys., 397, 184–190.
   Web of Science ®Google Scholar
• Amici, A., Emanuelli, M., Raffaelli, N., Ruggieri, S. and Magni, G. (1999) "Pyrimidine nucleotidases/phosphotransferases from hu-man erythrocyte", Nucleosides Nucleotides, 18, 853–855.
   PubMed Web of Science ®Google Scholar
• Rampazzo, C., Gallinaro, L., Milanesi, E., Frigimelica, E., Reichard, P. and Bianchi, V. (2000) "A deoxyribonucleotidase in mitochondria: involvement in regulation of dNTP pools and possible link to genetic disease", Proc. Natl. Acad. Sci. USA, 97, 8239— 8244.
   PubMed Web of Science ®Google Scholar
• Schirmer, M., Stegmann, A.P., Geisen, F. and Konwalinka, G. (1998) "Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity", Exp. HematoL, 26, 1223 — 1228.
   Web of Science ®Google Scholar
• Mazzon, C., Rampazzo, C., Scaini, MC., Gallinaro, L., Karlsson, A., Meier, C., et al. (2003) "Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy", Biochem. Pharmacol., 66, 471 —479.
   Web of Science ®Google Scholar
• Galmarini, CM., Graham, K., Thomas, X., Calvo, F., Rousselot, P., El Jafaari, A., et al. (2001) "Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia", Blood, 98, 1922–1926.
   Web of Science ®Google Scholar
• Capizzi, R.L., White, J.C., Powell, B.L. and Perrino, F. (1991) "Effect of dose on the pharmacolcinetic and pharmacodynamic effects of cytarabine", Semin. Hematol., 28, 54–69.
   Web of Science ®Google Scholar
• Honma, Y., Onozuka, Y., Okabe-Kado, J., Kasukabe, T. and Hozumi, M. (1991) "Hemin enhances the sensitivity of erythro-leukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine lcinase and reduction of cytidine deaminase activity", Cancer Res., 51, 4535 —4538.
   Google Scholar
• Momparler, R.L. and Laliberte, J. (1990) "Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycy-tidine", Leuk. Res., 14, 751–754.
   Google Scholar
• Momparler, R.L., Eliopoulos, N., Bovenzi, V., Letourneau, S., Greenbaum, M. and Cournoyer, D. (1996) "Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells", Cancer Gene Ther., 3, 331–338.
   PubMed Web of Science ®Google Scholar
• Schroder, J.K., Kirch, C., Flasshove, M., Kalweit, H., Seidelmann, M., Hilger, R., et al. (1996) "Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro", Leukemia, 10, 1919–1924.
   Google Scholar
• Neff, T. and Blau, C.A. (1996) "Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcita-bine", Exp. Hematol., 24, 1340— 1346.
   Web of Science ®Google Scholar
• Steuart, C.D. and Burke, P.J. (1971) "Cytidine deaminase and the development of resistance to arabinosyl cytosine", Nat. New Biol., 233, 109 — 110.
   Google Scholar
• Kirch, H.C., Schroder, J., Hoppe, H., Esche, H., Seeber, S. and Schutte, J. (1998) "Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro", Exp. Hematol., 26, 421 — 425.
   Web of Science ®Google Scholar
• Schroder, J.K., Kirch, C., Seeber, S. and Schutte, J. (1998) "Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia", Br. J. HaematoL, 103, 1096— 1103.
   Web of Science ®Google Scholar
• Chabner, B.A., Hande, K.R. and Drake, J.C. (1979) "Ara-C metabolism: implications for drug resistance and drug interac-tions", Bull. Cancer, 66, 89— 92.
   Web of Science ®Google Scholar
• Liliemark, J.0. and Plunkett, W. (1986) "Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate", Cancer Res., 46, 1079 — 1083.
   Google Scholar
• Kunz, B.A. (1988) "Mutagenesis and deoxyribonucleotide pool imbalance", Mutat. Res., 200, 133–147.
   Google Scholar
• Meuth, M. (1989) "The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells", Exp. Cell Res., 181, 305 — 316.
   Web of Science ®Google Scholar
• Ohno, Y., Spriggs, D., Matsukage, A., Ohno, T. and Kufe, D. (1988) "Effects of 1-beta-D-arabinofuranosylcytosine incorpora-tion on elongation of specific DNA sequences by DNA polymerase beta", Cancer Res., 48, 1494 — 1498.
   Google Scholar
• Fritzer-Szekeres, M., Salamon, A., Grusch, M., Horvath, Z., Hochtl, T., Steinbrugger, R., et al. (2002) "Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells", Biochem. Pharmacol., 64, 481–485.
   Web of Science ®Google Scholar
• Verschuur, AC., Van Gennip, A.H., Leen, R., Voute, PA., Brinkman, J. and Van Kuilenburg, A.B. (2002) "Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1-beta-D-arabinofuranosyl cytosine in a human T-lymphoblastic cell line", Int. J. Cancer, 98, 616 — 623.
   Web of Science ®Google Scholar
• Yoshida, S., Yamada, M. and Masalci, S. (1977) "Inhibition of DNA polymerase-alpha and -beta of calf thymus by 1-beta-D-arabinofuranosylcytosine-5'-triphosphate", Biochim. Biophys. Acta, 477, 144–150.
   PubMed Web of Science ®Google Scholar
• Wills, P.W., Hickey, R. and Malkas, L. (2000) "Ara-C differen-tially affects multiprotein forms of human cell DNA polymerase", Cancer Chemother. PharmacoL, 46, 193–203.
   Web of Science ®Google Scholar
• Harrington, C. and Perrino, F.W. (1995) "The effects of cytosine arabinoside on RNA-primed DNA synthesis by DNA polymerase alpha-primase", J. BioL Chem., 270, 26664–26669.
   PubMed Web of Science ®Google Scholar
• Perrino, F.W. and Mekosh, H.L. (1992) "Incorporation of cytosine arabinoside monophosphate into DNA at internucleotide linkages by human DNA polymerase alpha", J. BioL Chem., 267, 23043 — 23051.
   PubMed Web of Science ®Google Scholar
• Tanaka, M. and Yoshida, S. (1982) "Altered sensitivity to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate of DNA polymerase alpha from leukemic blasts of acute lymphoblastic leukemia", Cancer Res., 42, 649–653.
   PubMed Web of Science ®Google Scholar
• Higashigawa, M., Ido, M., Nagao, Y., Kuwabara, H., Hori, H., Ohkubo, T., et al. (1991) "Decreased DNA polymerase sensitivity to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in P388 murine leukemic cells resistant to vincristine", Leuk. Res., 15, 675 — 681.
   Google Scholar
• Ross, D.D., Thompson, B.W., Jonecicis, C.C., Akman, S.A. and Schiffer, CA. (1986) "Metabolism of ara-C by blast cells from patients with ANLL", Blood, 68, 76–82.
   Google Scholar
• Ho, Y.K., Reddy, A.R., Aradi, J., Minowada, J. and Bardos, Ti. (1985) "Inhibition of DNA polymerase alpha from leukemic and normal human cells by partially thiolated human deoxyribonucleic acids", Cancer Biochem. Biophys., 8, 85–94.
   Google Scholar
• Wang, J.C. (1991) "DNA topoisomerases: why so many?" J. Biol. Chem., 266, 6659–6662.
   PubMed Web of Science ®Google Scholar
• Martincic, D., Kravtsov, V., Whitlock, J.A. and Dumontet, C. (1999) "Sensitivity of HEL and K562 cell lines to topotecan correlates with the level of topoisomerase I expression activity", Proc. Am. Assoc. Cancer Res., 40, A719.
   Google Scholar
• Goz, B. and Bastow, K.F. (1997) "A possible role for topoisome-rase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine", Mutat. Res., 384, 89–106.
   Google Scholar
• Cline, S.D. and Osheroff, N. (1999) "Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes", J. BioL Chem., 274, 29740–29743.
   PubMed Web of Science ®Google Scholar
• Kaufmann, S.H., Karp, J.E., Jones, R.J., Miller, C.B., Schneider, E., Zwelling, L.A., et al. (1994) "Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia", Blood, 83, 517 — 530.
   Google Scholar
• Lohri, A., van Hille, B., Bacchi, M., Fopp, M., Joncourt, F., Reuter, J., et al. (1997) "Five putative drug resistance parameters (MDRUP-glycoprotein, MDR-associated protein, glutathione-S-transferase, bc1-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK)", Eur. J. HaematoL, 59, 206–215.
   PubMed Web of Science ®Google Scholar
• Plunkett, W., Iacoboni, S., Estey, E., Danhauser, L., Liliemark, J.0. and Keating, M.J. (1985) "Pharmacologically directed ara-C therapy for refractory leukemia", Semin. Oncol., 12, 20–30.
   PubMed Web of Science ®Google Scholar
• Spasokoukotskaja, T., Sasvari-Szekely, M., Keszler, G., Albertioni, F., Eriksson, S. and Staub, M. (1999) "Treatment of normal and malignant cells with nucleoside analogues and etopo-side enhances deoxycytidine kinase activity", Eur. J. Cancer, 35, 1862— 1867.
   Web of Science ®Google Scholar
• Spasokoukotskaja, T., Sasvari-Szekely, M., Hullan, L., Albertioni, F., Eriksson, S. and Staub, M. (1998) "Activation of deoxycytidine kinase by various nucleoside analogues", Adv. Exp. Med. Biol., 431, 641–645.
   Google Scholar
• Csapo, Z., Keszler, G., Safrany, G., Spasokoukotskaja, T., Talianidis, I., Staub, M., et al. (2003) "Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes", Biochem. Pharmacol., 65, 2031 — 2039.
   Web of Science ®Google Scholar
• Van Den Neste, E., Smal, C., Cardoen, S., Delacauw, A., Frankard, J., Ferrant, A., et al. (2003) "Activation of deoxycyti-dine kinase by UV-C-irradiation in chronic lymphocytic leukemia B-lymphocytes", Biochem. Pharmacol., 65, 573–580.
   Web of Science ®Google Scholar
• Galmarini, C.M., Mackey, J.R. and Dumontet, C. (2002) "Nucleoside analogues and nucleobases in cancer treatment", Lancet Oncol., 3, 415–424.
   PubMed Web of Science ®Google Scholar
• Galmarini, C.M., Clarke, M.L., Santos, C.L., Jordheim, L., Perigaud, C., Gosselin, G., et al. (2003) "Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue", Interna-tional Journal of Cancer, 107, 149 — 154.
   Google Scholar
• Schlienger, N., Peyrottes, S., Kassem, T., Imbach, J.L., Gosselin, G., Aubertin, A.M. and Perigaud, C. (2000) "S-Acy1-2-thioethyl aryl phosphotriester derivatives as mononucleotide prodrugs", J. Med. Chem., 43, 4570–4574.
   Web of Science ®Google Scholar
• Beltran, T., Egron, D., Pompon, A., Lefebvre, I., Perigaud, C., Gosselin, G., et al. (2001) "Rational design of a new series of pronucleotide", Bioorg. Med. Chem. Lett., 11, 1775–1777.
   Web of Science ®Google Scholar
• Iwasaki, H., Huang, P., Keating, M.J. and Plunkett, W. (1997) "Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells", Blood, 90, 270 — 278.
   Google Scholar
• Gandhi, V. and Plunkett, W. (1988) "Modulation of arabinosyl-nucleoside metabolism by arabinosylnucleotides in human leuke-mia cells", Cancer Res., 48, 329–334.
   PubMed Web of Science ®Google Scholar
• Gandhi, V., Kemena, A., Keating, M.J. and Plunkett, W. (1992) "Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia", Cancer Res., 52, 897–903.
   PubMed Web of Science ®Google Scholar
• Suki, S., Kantarjian, H., Gandhi, V., Estey, E., O'Brien, S., Beran, M., et al. (1993) "Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia", Cancer, 72, 2155–2160.
   PubMed Web of Science ®Google Scholar
• Gandhi, V., Nowak, B., Keating, M.J. and Plunkett, W. (1989) "Modulation of arabinosylcytosine metabolism by arabinosy1-2-fluoroadenine in lymphocytes from patients with chronic lympho-cytic leukemia: implications for combination therapy", Blood, 74, 2070— 2075.
   Google Scholar
• Gandhi, V., Estey, E., Keating, M.J. and Plunkett, W. (1993) "Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy", J. Clin. Oncol., 11, 116–124.
   Web of Science ®Google Scholar
• Gandhi, V., Robertson, L.E., Keating, M.J. and Plunkett, W. (1994) "Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology", Cancer Chemother. Pharmacol., 34, 30— 36.
   Web of Science ®Google Scholar
• Seymour, J.F., Huang, P., Plunkett, W. and Gandhi, V. (1996) "Influence of fludarabine on pharmacokinetics and pharmacody-namics of cytarabine: implications for a continuous infusion schedule", Clin. Cancer Res., 2, 653–658.
   Web of Science ®Google Scholar
• Keating, M.J., Estey, E., O'Brien, S., Kantarjian, H., Robertson, L.E. and Plunkett, W. (1994) "Clinical experience with fludarabine in leukaemia", Drugs, 47\(Suppl 6), 39–49.
   PubMedGoogle Scholar
• Avramis, V.I., Wiersma, S., Krailo, M.D., Ramilo-Torno, L.V., Sharpe, A., Liu-Mares, W., et al. (1998) "Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group", Clin. Cancer Res., 4, 45–52.
   PubMed Web of Science ®Google Scholar
• Colly, L.P., Richel, D.J., Arentsen-Honders, M.W., Kester, M.G., ter Riet, P.M. and Willemze, R. (1992) "Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimula-tion of the salvage and inhibition of the de novo pathway", Ann. Hematol., 65, 26–32.
   Web of Science ®Google Scholar
• Bhalla, K., Swerdlow, P. and Grant, S. (1991) "Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells", Blood, 78, 2937 — 2944.
   Google Scholar
• Gandhi, V., Estey, E., Keating, M.J. and Plunkett, W. (1993) "Biochemical modulation of arabinosylcytosine for therapy of leukemias", Leuk. Lymphoma, 10(Suppl), 109 — 114.
   Google Scholar
• Gandhi, V., Estey, E., Keating, M.J., Chucrallah, A. and Plunkett, W. (1996) "Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions", Blood, 87, 256 — 264.
   Google Scholar